Assignee
TRANSGENE SA
US·131 granted patents·23 pending applications·2,320 citations·filing 1987–2022
Top patents by PatentIndex Score
154 records- 0195US6040174ADefective adenoviruses and corresponding complementation linesTRANSGENE SA·Filed 1994·Granted Mar 21, 2000·212 cites·19 claims
- 0293US7670607B2Pharmaceutical compositions for treating papillomavirus tumors and infectionTRANSGENE SA·Filed 2008·Granted Mar 2, 2010·12 cites·21 claims
- 0393US7488482B2Pharmaceutical compositions for treating papillomavirus tumors and infectionTRANSGENE SA·Filed 2006·Granted Feb 10, 2009·24 cites·15 claims
- 0493US5112950AFactor viii analog, preparation process, and pharmaceutical composition containing itTRANSGENE SA·Filed 1991·Granted May 12, 1992·195 cites·6 claims
- 0592US7067310B2Method for the preparation of a viral vector by inter-molecular homologous recombinationTRANSGENE SA·Filed 2001·Granted Jun 27, 2006·40 cites·17 claims
- 0691US7572438B2Mutant having uracil phosphoribosyl transferase activityTRANSGENE SA·Filed 2005·Granted Aug 11, 2009·12 cites·7 claims
- 0790US6335199B1Lipid compounds and compositions containing same used for the transfer of at least an active substance, in particular a polynucleotide, in a target cell and therapeutic useTRANSGENE SA·Filed 1998·Granted Jan 1, 2002·110 cites·41 claims
- 0889US6350575B1Helper viruses for the preparation of recombinant viral vectorsTRANSGENE SA·Filed 2000·Granted Feb 26, 2002·25 cites·34 claims
- 0988US10555981B2Oncolytic virus for expression of immune checkpoint modulatorsTRANSGENE SA·Filed 2015·Granted Feb 11, 2020·9 cites·15 claims
- 1087US7118754B1Pharmaceutical composition for treating papillomavirus tumors and infectionTRANSGENE SA·Filed 2000·Granted Oct 10, 2006·22 cites·15 claims
- 1186US10190105B2HBV polymerase mutantsTRANSGENE SA·Filed 2016·Granted Jan 29, 2019·5 cites·40 claims
- 1286US6271208B1Process of making cationic lipid-nucleic acid complexesTRANSGENE SA·Filed 1997·Granted Aug 7, 2001·79 cites·35 claims
- 1386US6007806AExpression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventive or curative treatment of the corresponding tumorTRANSGENE SA·Filed 1997·Granted Dec 28, 1999·77 cites·20 claims
- 1485US7148341B2AAV DNA comprising helper virus sequencesTRANSGENE SA·Filed 2001·Granted Dec 12, 2006·16 cites·15 claims
- 1584US6204060B1Viral vectors and line for gene therapyTRANSGENE SA·Filed 1996·Granted Mar 20, 2001·66 cites·42 claims
- 1684US6133028ADefective adenoviruses and corresponding complementation linesTRANSGENE SA·Filed 1999·Granted Oct 17, 2000·74 cites·33 claims
- 1784US6110735AMethod for the preparation of a viral vector by intermolecular homologous recombinationTRANSGENE SA·Filed 1995·Granted Aug 29, 2000·62 cites·18 claims
- 1883US5861381APharmaceutical composition for the treatment of a malignant tumorTRANSGENE SA·Filed 1995·Granted Jan 19, 1999·55 cites·13 claims
- 1983US5631144AApplication of novel DNA fragments as a coding sequence for a signal peptide for the secretion of mature proteins by recombinant yeast, expression cassettes, transformed yeast and corresponding process for the preparation of proteinsTRANSGENE SA·Filed 1995·Granted May 20, 1997·60 cites·25 claims
- 2082US11779619B2Oncolytic virus for expression of immune checkpoint modulatorsTRANSGENE SA·Filed 2019·Granted Oct 10, 2023·1 cites·21 claims
- 2182US9687515B2Poxviral oncolytic vectorsTRANSGENE SA·Filed 2014·Granted Jun 27, 2017·3 cites·14 claims
- 2282US9295702B2Process for producing poxviruses and poxvirus compositionsTRANSGENE SA·Filed 2014·Granted Mar 29, 2016·4 cites·19 claims
- 2382US6136594AReplication deficient recombinant adenovirus vectorTRANSGENE SA·Filed 1995·Granted Oct 24, 2000·34 cites·15 claims
- 2481US7264958B1Method for obtaining a purified viral preparationTRANSGENE SA·Filed 2000·Granted Sep 4, 2007·18 cites·19 claims
- 2581US6906041B2Treatment of immune diseasesTRANSGENE SA·Filed 2001·Granted Jun 14, 2005·19 cites·9 claims
- 2681US6884786B1Antitumoral composition based on immunogenic polypeptide with modified cell locationTRANSGENE SA·Filed 1998·Granted Apr 26, 2005·46 cites·34 claims
- 2781US6291423B1Lipid complexes for transferring at least a therapeutically active substance, in particular a polynucleotide into a target cell and use in gene therapyTRANSGENE SA·Filed 1998·Granted Sep 18, 2001·30 cites·7 claims
- 2881US6281000B1Method for the preparation of a viral vector by intermolecular homologous recombinationTRANSGENE SA·Filed 1999·Granted Aug 28, 2001·45 cites·1 claims
- 2980US6740511B1Modified adenoviral fibre and uses thereofTRANSGENE SA·Filed 2000·Granted May 25, 2004·10 cites·5 claims
- 3080US5795577AViral vector coding for a glycoprotein of the virus responsible for A.I.D.S.TRANSGENE SA·Filed 1995·Granted Aug 18, 1998·46 cites·55 claims
- 3179US9139652B2Method for increasing M1 macrophages in a patientTRANSGENE SA·Filed 2012·Granted Sep 22, 2015·8 cites·14 claims
- 3279US7695960B2Composition comprising the polyprotein NS3/NS4 and the polypeptide NS5B of HCV, expression vectors including the corresponding nucleic sequences and their therapeutic useTRANSGENE SA·Filed 2007·Granted Apr 13, 2010·7 cites·32 claims
- 3378US7393831B2Peptide compositions and their use against HCVTRANSGENE SA·Filed 2003·Granted Jul 1, 2008·10 cites·12 claims
- 3477US9982055B2Antibody against the CSF-1RTRANSGENE SA·Filed 2016·Granted May 29, 2018·2 cites·18 claims
- 3576US7947288B2Viral particles encoding multifunctional cytokinesTRANSGENE SA·Filed 2009·Granted May 24, 2011·3 cites·16 claims
- 3676US6569677B1Modified adenoviral fiber and target adenovirusesTRANSGENE SA·Filed 1998·Granted May 27, 2003·34 cites·10 claims
- 3775US7378265B2Method of inactivating enveloped viruses in a viral preparation of non-enveloped virusesTRANSGENE SA·Filed 2005·Granted May 27, 2008·1 cites·29 claims
- 3874US9428584B2Antibody against the CSF-1RTRANSGENE SA·Filed 2013·Granted Aug 30, 2016·2 cites·18 claims
- 3974US7892828B2Method of identifying a MHC class I restricted T cell responseTRANSGENE SA·Filed 2009·Granted Feb 22, 2011·3 cites·3 claims
- 4074US7067309B2Defective adenoviruses and corresponding complementation linesTRANSGENE SA·Filed 2000·Granted Jun 27, 2006·2 cites·4 claims
- 4174US7005277B2Defective adenoviruses and corresponding complementation linesTRANSGENE SA·Filed 2000·Granted Feb 28, 2006·2 cites·8 claims
- 4274US6258791B1Combination product for enhanced gene delivery comprising a hyaluronidaseTRANSGENE SA·Filed 1998·Granted Jul 10, 2001·43 cites·13 claims
- 4374US5744133AExpression of a tumor-specific antigen by a recombinant vector virus and use thereof in preventitive or curative treatment of the corresponding tumorTRANSGENE SA·Filed 1994·Granted Apr 28, 1998·48 cites·26 claims
- 4473US9221912B2Antibody against the CSF-1RTRANSGENE SA·Filed 2013·Granted Dec 29, 2015·2 cites·19 claims
- 4573US8357531B2Immortalized avian cell linesTRANSGENE SA·Filed 2010·Granted Jan 22, 2013·1 cites·6 claims
- 4672US6960469B2Adenoviral vectors encoding an antibody fused to a CD4 extracellular domainTRANSGENE SA·Filed 2001·Granted Nov 1, 2005·2 cites·10 claims
- 4772US6596533B1Mutant having uracil phosphoribosyl transferase activityTRANSGENE SA·Filed 1999·Granted Jul 22, 2003·23 cites·12 claims
- 4872US6514756B1Human myoblast cell lines and their usesTRANSGENE SA·Filed 2000·Granted Feb 4, 2003·4 cites·6 claims
- 4971US7608267B2Multifunctional cytokinesTRANSGENE SA·Filed 2004·Granted Oct 27, 2009·6 cites·25 claims
- 5071US7049117B2Mutant possessing uracil phosphoribosyl transferase activityTRANSGENE SA·Filed 2003·Granted May 23, 2006·4 cites·9 claims
Showing the top 50 of 154 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →